Intermediate for Olaparib. Olaparib (trade name Lynparza) is a PARP inhibitor for the treatment of germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. Olaparib has been approved by the U.S Food and Drug Administration on December 19, 2014.
Product Name: 2-Fluoro-5-((3-oxo-1(3H)-isobenzofuranylidene)methyl)-benzonitrile
CAS Number: 763114-25-6
Molecular Weight:  265.2431
Molecular Formula:  C16H8FNO2
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.